Get started

Financials · KPTI

Karyopharm Therapeutics Inc. (KPTI) financials

For the twelve months ended Jun 30, 2026, Karyopharm Therapeutics Inc. reported $146.62M of revenue and -$224.74M of net income.

Revenue, TTM
$146.62M
Revenue growth, YoY
+6.8%
Net income, TTM
-$224.74M
Net margin
-153.3%
Cash
$54.98M
P/S
0.01
Market cap
$1.2M
Annual revenue$146.07M
FY2016FY2025
Annual net income-$196.04M
FY2016FY2025
Annual free cash flow-$75.37M
FY2016FY2025

KPTI revenue and earnings growth

KPTI revenueQ2 2026$33.43M

Quarter YoY
-11.9%
QoQ
-4.7%
FY YoY
+0.6%
5Y CAGR
+6.2%
10Y CAGR
+89.1%

KPTI revenue was $33.43M in fiscal Q2 2026 (ended Jun 30, 2026), down 11.9% from a year earlier and down 4.7% from the prior quarter. For the full fiscal 2025 it was $146.07M, up 0.6% from fiscal 2024. Compound annual growth was +6.2% over 5 years and +89.1% over 10 years. It rose in 6 of the last 10 fiscal years.

KPTI net incomeQ2 2026-$67.02M

KPTI net income was -$67.02M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$37.25M a year earlier. For the full fiscal 2025 it was -$196.04M, compared with -$76.42M in fiscal 2024.

KPTI EPSQ2 2026-$2.32

KPTI diluted EPS was -$2.32 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$17.93, compared with -$14.00 in fiscal 2024.

KPTI free cash flowQ4 2025-$11.83M

KPTI free cash flow was -$11.83M in fiscal Q4 2025 (ended Dec 31, 2025), compared with -$25.86M a year earlier. For the full fiscal 2025 it was -$75.37M, compared with -$127.63M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$146.07M$145.24M$146.03M$157.07M$209.82M$108.08M$40.89M$30.34M$1.60M$154.0K
Research and development$125.62M$143.23M$138.75M$148.66M$160.84M$150.81M$122.34M$161.37M$107.27M$86.94M
Selling, general and admin$105.21M$115.44M$131.88M$145.40M$143.85M$126.42M$105.42M$48.85M$24.87M$23.95M
Operating income-$90.71M-$119.44M-$129.54M-$142.20M-$98.27M-$171.85M-$189.28M-$179.88M-$130.54M-$110.73M
Interest expense$45.85M$37.42M$23.82M$25.00M$26.05M$27.14M$15.65M$2.49M--
Pre-tax income-$196.00M-$76.36M-$142.78M-$164.92M-$123.82M-$195.96M-$199.55M-$178.38M-$128.92M-$109.44M
Income tax$43.0K$57.0K$323.0K$369.0K$268.0K$309.0K$40.0K$26.0K$63.0K$139.0K
Net income-$196.04M-$76.42M-$143.10M-$165.29M-$124.09M-$196.27M-$199.59M-$178.41M-$128.98M-$109.58M
EPS, basic-$17.93-$9.41-$18.79-$30.30-$24.75-$40.80-$48.30-$47.10-$42.15-$43.80
EPS, diluted-$17.93-$14.00-$18.79-$30.30-$24.75-$40.80-$48.30-$47.10-$42.15-$43.80
Diluted shares10,9358,4557,6165,458.0675.0M4.8M4.1M3,785.3333.1M2.5M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$60.54M$62.81M$52.23M$136.88M$197.44M$89.12M$130.69M$118.74M$69.49M$50.14M
Short-term investments--------$77.47M$79.89M
Receivables$26.18M$30.77M$26.96M$47.09M$22.50M$12.88M$7.86M---
Inventory$4.04M$4.74M$3.04M$4.22M$4.11M$2.64M$346.0K---
Current assets$103.15M$156.46M$233.92M$350.16M$275.61M$276.53M$278.57M$334.61M$148.42M$131.64M
Total assets$108.42M$164.42M$240.44M$358.17M$305.31M$313.05M$294.96M$341.19M$180.29M$180.38M
Current liabilities$92.06M$92.26M$69.48M$65.91M$73.72M$60.20M$46.35M$46.90M$49.47M$16.48M
Long-term debt-$0$170.92M$170.10M$169.29M$117.93M$109.86M$102.66M--
Total debt-$0$170.92M$170.10M$169.29M$117.93M$109.86M$102.66M--
Total liabilities$401.34M$350.44M$376.64M$374.83M$384.98M$262.50M$245.19M$158.02M$50.83M$18.14M
Shareholders' equity-$292.93M-$186.02M-$136.21M-$16.66M-$79.67M$50.55M$49.77M$183.17M$129.46M$162.24M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$75.37M-$127.49M-$92.72M-$149.55M-$107.12M-$160.23M-$190.82M-$159.12M-$73.72M-$84.39M
Capital expenditures$0$142.0K$0$118.0K$212.0K$145.0K$206.0K$2.36M$62.0K$70.0K
Free cash flow-$75.37M-$127.63M-$92.72M-$149.67M-$107.33M-$160.38M-$191.03M-$161.48M-$73.78M-$84.46M
Investing cash flow$43.38M$95.47M$7.94M-$104.26M$141.84M-$53.69M$78.45M-$107.66M$17.11M$24.59M
Financing cash flow$30.05M$41.65M$1.12M$193.74M$73.65M$172.08M$124.31M$316.11M$75.74M$51.16M
Stock-based compensation$14.05M$18.43M$21.71M$35.40M$29.78M$24.41M$15.29M$17.27M$20.41M$22.28M
Depreciation and amortization------$974.0K$735.0K$713.0K$717.0K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY0.6%-0.5%-7.0%-25.1%94.1%164.3%34.8%1790.1%942.2%-38.4%
Operating margin-62.1%-82.2%-88.7%-90.5%-46.8%-159.0%-462.9%-593.0%-8133.2%-71903.9%
Net margin-134.2%-52.6%-98.0%-105.2%-59.1%-181.6%-488.1%-588.1%-8036.4%-71153.9%
Free cash flow margin-51.6%-87.9%-63.5%-95.3%-51.2%-148.4%-467.1%-532.3%-4596.8%-54844.8%
Return on equity------388.3%-401.0%-97.4%-99.6%-67.5%
Return on assets-180.8%-46.5%-59.5%-46.1%-40.6%-62.7%-67.7%-52.3%-71.5%-60.7%
Current ratio1.121.703.375.313.744.596.017.133.007.99
Debt to equity-----2.332.210.56--

Source: XBRL data Karyopharm Therapeutics Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-15, first reported Nov 3, 2025.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

KPTI peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
KPTI$146.62M+6.8%-$224.74M-153.3%$1.2M
LLY$86.46B+45.5%$27.58B31.9%$1.27T
JNJ$99.33B+7.8%$16.09B16.2%$664.95B
ABBV$66.01B+10.7%$10.34B15.7%$514.92B
MRK$67.38B+4.9%$2.45B3.6%$361.71B
NVS$54.53B+8.4%$13.98B25.6%$310.17B
AZN$58.74B+8.6%$10.22B17.4%$289.10B
ABT$48.23B+10.0%$4.70B9.7%$190.39B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$178.51B

KPTI FAQ

6 questions
  • What is KPTI revenue?
    Karyopharm Therapeutics Inc. (KPTI) reported $146.62M of revenue for the twelve months ended Jun 30, 2026. That is up 6.8% from the year before. Revenue for fiscal 2025 was $146.07M.
  • Is KPTI profitable?
    No. Karyopharm Therapeutics Inc. reported a net loss of $224.74M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does KPTI have?
    Karyopharm Therapeutics Inc. reported $54.98M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is KPTI revenue growing?
    Karyopharm Therapeutics Inc.'s revenue changed +0.6% in fiscal 2025, to $146.07M. Its compound annual growth rate was +6.2% over 5 years and +89.1% over 10 years.
  • When did KPTI last report financial results?
    The latest statements here come from Karyopharm Therapeutics Inc.'s 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.
  • Where does this KPTI financial data come from?
    Quantisnow builds these statements from the structured XBRL data Karyopharm Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.